Comment
doi: 10.1016/s0140-6736(98)85003-4.
Routine use of abciximab in coronary stenting?
Affiliations
- PMID: 9672267
- DOI: 10.1016/s0140-6736(98)85003-4
Item in Clipboard
Comment
Routine use of abciximab in coronary stenting?
Lancet.
.
No abstract available
Comment on
-
Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.Lancet. 1998 Jul 11;352(9122):87-92. doi: 10.1016/s0140-6736(98)06113-3. Lancet. 1998. PMID: 9672272 Clinical Trial.
Similar articles
-
Platelet glycoprotein IIb/IIIa receptor blockade after coronary angioplasty.N Engl J Med. 1997 Oct 23;337(17):1243; author reply 1244-5. doi: 10.1056/NEJM199710233371716. N Engl J Med. 1997. PMID: 9340527 No abstract available.
-
Economics of coronary stenting and GPIIb/IIIa blockade.Eur Heart J. 2001 Aug;22(16):1366-8. doi: 10.1053/euhj.2001.2704. Eur Heart J. 2001. PMID: 11482914 No abstract available.
-
Should glycoprotein IIb/IIIa inhibitors be used during all percutaneous coronary interventions? Yes.J Thromb Haemost. 2004 Jan;2(1):7-9. doi: 10.1111/j.1538-7836.2004.00559.x. J Thromb Haemost. 2004. PMID: 14717958 Review. No abstract available.
-
Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators.N Engl J Med. 1999 Jul 29;341(5):319-27. doi: 10.1056/NEJM199907293410503. N Engl J Med. 1999. PMID: 10423466 Clinical Trial.
-
Economic issues in glycoprotein IIb/IIIa receptor therapy.Am Heart J. 1999 Jul;138(1 Pt 2):S24-32. doi: 10.1053/hj.1999.v138.99079. Am Heart J. 1999. PMID: 10385788 Review.
Cited by
-
Abciximab. An updated review of its use in ischaemic heart disease.Drugs. 1998 Oct;56(4):629-65. doi: 10.2165/00003495-199856040-00014. Drugs. 1998. PMID: 9806109 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
